EYPT

EyePoint Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website eyepointpharma.com
Employees(FY) 144
ISIN US30233G2093

Performance

-10.58%

-22.91%

-22.66%

-18.3%

-69.28%

YTD

-63.33%

Profile

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Advanced Technical Analysis

Technical Analysis of EYPT 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of EYPT

Stock Rank

Recent News & Updates

2024-12-16 18:25
EyePoint reports inducement grants under NASDAQ listing rule(Yahoo Finance)
2024-12-16 18:00
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference(Yahoo Finance)
2024-12-15 18:00
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Globenewswire)
2024-12-04 18:06
EyePoint doses first patient in second Phase 3 LUCIA clinical trial(Yahoo Finance)
2024-12-03 18:00
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration(Globenewswire)
2024-11-18 07:00
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(GlobeNewswire)
2024-11-17 18:00
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Globenewswire)
2024-11-13 09:55
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?(Zacks)
2024-11-12 06:45
EyePoint price target lowered to $33 from $38 at Baird(TipRanks)
2024-11-09 08:04
EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags(Simply Wall St.)
2024-11-07 08:35
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates(Zacks)
2024-11-07 07:37
EyePoint Pharmaceuticals: Q3 Earnings Snapshot(Associated Press Finance)
2024-11-07 07:00
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments(GlobeNewswire)
2024-11-06 18:00
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments(Globenewswire)
2024-11-05 05:10
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing(Simply Wall St.)
2024-11-04 07:00
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences(GlobeNewswire)
2024-11-03 18:00
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences(Globenewswire)
2024-10-31 16:00
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares(GlobeNewswire)
2024-10-31 04:00
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares(Globenewswire)
2024-10-30 04:13
EyePoint Pharmaceuticals Prices $140 Million Public Offering(MT Newswires)
2024-10-29 21:47
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering(GlobeNewswire)
2024-10-29 09:47
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering(Globenewswire)
2024-10-29 04:49
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?(Zacks)
2024-10-28 17:14
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock(GlobeNewswire)
2024-10-28 12:16
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss(Benzinga)
2024-10-28 07:00
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema(GlobeNewswire)
2024-10-28 05:14
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock(Globenewswire)
2024-10-27 19:00
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema(Globenewswire)
2024-10-24 07:00
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration(GlobeNewswire)
2024-10-23 19:00
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration(Globenewswire)

Page 1 of 9

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.